دورية أكاديمية
Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.
| العنوان: | Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens. |
|---|---|
| المؤلفون: | Lodise TP; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA., Kaye KS; Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA., Santerre Henriksen A; Maxel Consulting ApS, Jyllinge, Denmark., Kahlmeter G; Department of Clinical Microbiology, Central Hospital, Växjö, Sweden. |
| المصدر: | Open forum infectious diseases [Open Forum Infect Dis] 2024 May 24; Vol. 11 (6), pp. ofae296. Date of Electronic Publication: 2024 May 24 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Published by Oxford University Press on behalf of the Infectious Diseases Society of America Country of Publication: United States NLM ID: 101637045 Publication Model: eCollection Cited Medium: Print ISSN: 2328-8957 (Print) Linking ISSN: 23288957 NLM ISO Abbreviation: Open Forum Infect Dis Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Cary, NC : Published by Oxford University Press on behalf of the Infectious Diseases Society of America, [2014]- |
| مستخلص: | Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for Escherichia coli to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing E. coli -exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including Klebsiella spp., Enterobacter spp., and Citrobacter spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI. Competing Interests: Potential conflicts of interest. T.L.: consultant and advisory board member for UTILITY therapeutics. K.S.K.: consultant for AbbVie, CARB-X, GSK, Merck, and Shionogi. A.S.H.: consultant for UTILITY therapeutics. G.K.: no conflicts of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.) |
| References: | J Chemother. 2007 Apr;19(2):222-5. (PMID: 17434833) Clin Microbiol Infect. 2021 Oct;27(10):1381-1382. (PMID: 34271182) APMIS. 2011 Dec;119(12):853-63. (PMID: 22085361) PLoS Med. 2018 May 15;15(5):e1002569. (PMID: 29763434) J Antimicrob Chemother. 2019 Sep 1;74(9):2767-2773. (PMID: 31098630) J Glob Antimicrob Resist. 2019 Jun;17:25-34. (PMID: 30447337) Antibiotics (Basel). 2022 May 31;11(6):. (PMID: 35740157) Scand J Prim Health Care. 2007 Mar;25(1):49-57. (PMID: 17354160) Postgrad Med. 2020 Apr;132(3):234-250. (PMID: 31608743) Infect Dis (Lond). 2016 Feb;48(2):99-107. (PMID: 26414659) Clin Microbiol Infect. 2015 Oct;21(10):899-905. (PMID: 26027916) J Antimicrob Chemother. 2003 Jan;51(1):69-76. (PMID: 12493789) Med Mal Infect. 2016 Dec;46(8):436-441. (PMID: 27609597) Antimicrob Agents Chemother. 1976 Dec;10(6):872-7. (PMID: 1051328) Antimicrob Agents Chemother. 2019 Mar 27;63(4):. (PMID: 30917983) Int J Antimicrob Agents. 2009 Nov;34(5):407-13. (PMID: 19505803) Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2429-37. (PMID: 26433746) Scand J Infect Dis. 2002;34(7):487-92. (PMID: 12195873) BMC Infect Dis. 2014 Mar 11;14:137. (PMID: 24612927) Eur J Clin Microbiol Infect Dis. 2011 Aug;30(8):981-7. (PMID: 21298459) Scand J Infect Dis. 2010 Apr;42(4):243-8. (PMID: 20085420) Nat Rev Microbiol. 2015 May;13(5):269-84. (PMID: 25853778) Int J Antimicrob Agents. 2000 Jan;13(3):183-7. (PMID: 10724022) Pathology. 2021 Oct;53(6):803-805. (PMID: 33526242) Antimicrob Agents Chemother. 2016 Apr 22;60(5):2680-3. (PMID: 26883714) J Antimicrob Chemother. 2012 Oct;67(10):2424-8. (PMID: 22665388) BMC Geriatr. 2014 Mar 13;14:30. (PMID: 24625344) Int J Antimicrob Agents. 2018 Jul;52(1):100-103. (PMID: 29580930) Clin Infect Dis. 2021 Dec 6;73(11):1992-1999. (PMID: 34143881) BMC Infect Dis. 2016 Nov 3;16(1):620. (PMID: 27806687) Infect Dis Ther. 2015 Dec;4(4):417-23. (PMID: 26507395) Ther Adv Urol. 2019 May 02;11:1756287219832172. (PMID: 31105774) J Chemother. 2010 Oct;22(5):345-54. (PMID: 21123159) Pathogens. 2022 Mar 15;11(3):. (PMID: 35335681) Infect Drug Resist. 2019 Jun 13;12:1691-1702. (PMID: 31354318) JAC Antimicrob Resist. 2022 Jun 16;4(3):dlac059. (PMID: 35719201) J Antimicrob Chemother. 2022 Dec 23;78(1):289-295. (PMID: 36441168) Ceylon Med J. 2019 Dec 31;64(4):140-145. (PMID: 32120467) Clin Infect Dis. 2011 Mar 1;52(5):e103-20. (PMID: 21292654) Open Forum Infect Dis. 2018 Nov 16;5(11):ofy297. (PMID: 30539040) Front Microbiol. 2021 Jan 12;11:627267. (PMID: 33510739) Med Mal Infect. 2013 Feb;43(2):62-6. (PMID: 23433608) Acta Paediatr. 2004 Apr;93(4):487-91. (PMID: 15188976) Int J Antimicrob Agents. 2022 May;59(5):106574. (PMID: 35307561) Can J Infect Dis. 2001 Sep;12(5):289-92. (PMID: 18159352) Open Forum Infect Dis. 2017 Feb 24;4(1):ofw281. (PMID: 28480273) J Antimicrob Chemother. 2022 Sep 30;77(10):2835-2839. (PMID: 35815675) Int J Antimicrob Agents. 2012 Jan;39(1):45-51. (PMID: 22055529) J Glob Antimicrob Resist. 2022 Mar;28:18-29. (PMID: 34896337) BMC Infect Dis. 2022 Feb 28;22(1):194. (PMID: 35227203) J Infect Public Health. 2019 Nov - Dec;12(6):843-846. (PMID: 31176606) J Glob Antimicrob Resist. 2013 Mar;1(1):47-48. (PMID: 27873607) Antimicrob Agents Chemother. 2012 Apr;56(4):2181-3. (PMID: 22252813) Open Forum Infect Dis. 2021 Oct 15;8(10):ofab380. (PMID: 34660834) Int J Infect Dis. 2017 May;58:96-109. (PMID: 28341436) Tidsskr Nor Laegeforen. 2021 Jun 08;141(10):. (PMID: 34182746) J Antimicrob Chemother. 2022 Feb 2;77(2):537-538. (PMID: 34741607) |
| فهرسة مساهمة: | Keywords: ESBL; Enterobacterales; mecillinam; resistance; uncomplicated urinary tract infection |
| تواريخ الأحداث: | Date Created: 20240613 Latest Revision: 20240628 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC11167674 |
| DOI: | 10.1093/ofid/ofae296 |
| PMID: | 38868308 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2328-8957 |
|---|---|
| DOI: | 10.1093/ofid/ofae296 |